PolTREG Treg cell therapy for patients with type-1 diabetes shows long-term clinical remission and insulin independence PTG-007 cell therapy resulted in clinical remission in some patients for up to 12 yearsA proportion of patients remained insulin-independent for up to 24 monthsPTG-007 ready to enter pivotal studyData...

PolTREG receives CGMP certification to produce cell therapies at its state-of-the-art manufacturing site in Poland Gdańsk, Poland – 11 March 2024 – PolTREG S.A. (Warsaw Stock Exchange: PTG) , a clinical-stage biotechnology company developing cellular therapies for a range of autoimmune diseases, today announces it...